Inhibidores enzimaticos de la angiotensina II. (2da parte). Uso clínicos: actualidad y futuro

Rodríguez Gómez, R; López de Castro García, O; Guevara Chaviano, E; Alvarez Plasencia, A.
Gac méd espirit ; 9(2)mayo-ago, 2007.
Artigo em Espanhol | CUMED | ID: cum-35525

Documentos relacionados

  1. Development of a Digital Interface for Personalized Dosing in Renal Impaired Patients: A Case-Study Using the ACE-Inhibitor Benazepril.
  2. Pharmacological differentiation of angiotensin-converting enzyme inhibitors.
  3. Angiotensin-converting enzyme inhibitors. Emerging differences and new compounds.
  4. A sensitive and efficient LC-MS/MS method for the bioanalysis of fosinopril diacid from human plasma and its application for a bioequivalence study in humans.
  5. Office and ambulatory blood pressure control in hypertensive patients treated with different two-drug and three-drug combinations.
  6. [Comprehensive organoprotection in patients with high cardiovascular risk: the possibility of ramipril from positions of evidence-based medicine].
  7. In vivo hypotensive effect and in vitro inhibitory activity of some Cyperaceae species
  8. Indirect assessment of tissue angiotensin II converting enzyme inhibition in vivo in man.
  9. NIR hyperspectral imaging to evaluate degradation in captopril commercial tablets.
  10. The antihypertensive agents: clinical pharmacology and therapeutic monitoring.